PSEN2

Across TCGA pan-cancer cohorts, PSEN2 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated PSEN2 data layer compared with 23 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher PSEN2 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated PSEN2 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

LSCC, UCEC, and LUAD are the cancer types where PSEN2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	OS	Quartile	II,III,IV	0.719	1.000	.004	19	view →
UCEC	OS	Median	All	0.979	0.859	.021	2	view →
LUAD	DFS	Quartile	II,III,IV	0.738	1.000	.040	2	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

PSEN2–LSCC (OS)

Open the LSCC breakdown →